Geneva, July 14 -- International Clinical Trials Registry received information related to the study (ACTRN12625000694415) titled 'First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB201 in Healthy Adult Subjects' on July 1.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Rarefied Biosciences Australia PTY LTD
Condition:
autoimmunity
autoimmunity
Inflammatory and Immune System - Autoimmune diseases
Intervention:
Treatment: RB201 - small molecule inhibitor of MALT1
Dosage Formulation: Capsule
Route: Oral
Experimental:
Part 1: Single ...